Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Utility of Measuring Circulating Tumor Cell Counts to Assess the Efficacy of Treatment for Carcinomas of Unknown Primary Origin

KEIGO KOMINE, MASAHIRO INOUE, KAZUNORI OTSUKA, KOJI FUKUDA, HIROSHI NANJO and HIROYUKI SHIBATA
Anticancer Research June 2014, 34 (6) 3165-3168;
KEIGO KOMINE
1Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAHIRO INOUE
1Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUNORI OTSUKA
1Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOJI FUKUDA
1Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI NANJO
2Department of Clinical Pathology, Akita University Hospital, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI SHIBATA
1Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hiroyuki@med.akita-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Carcinomas of unknown primary origin (CUPs) account for 3%-5% of all malignancies. The majority of CUPs have unfavorable prognosis and are chemoresistant. Predictive biomarkers should be established to improve therapeutic outcomes. Metastatic ability of CUPs may be related to the existence of circulating tumor cells (CTCs). Patients and Methods: Ten patients diagnosed with CUP visiting the Akita University Hospital participated in this study. CTCs were calculated by the CellSearch system. Results: The present observational study indicates that CTCs were detected in 50% of CUPs, and in 80% chemotherapeutically-naïve cases. Furthermore, decrease in CTC count between the pre-treatment and post-treatment phases were observed in chemosensitive cases. Conclusion: Rapid assessment of the efficacy of chemotherapy by CTC count may become a useful predictive biomarker of CUPs.

  • Biomarker
  • carcinomas of unknown primary origin
  • chemotherapy
  • circulating tumor cell
  • prediction

Carcinomas of unknown primary origin (CUP) are defined as histopathologically-confirmed metastatic carcinomas with no primary site identified after completion of clinical examinations (1). Favorable subsets of CUP, including extragonadal germ cell cancer, peritoneal papillary adenocarcinoma, adenocarcinoma of the axillary lymph nodes (LN), cervical squamous cell carcinoma, neuroendocrine carcinoma (NEC), and bone metastasis with elevated prostate-specific antigen levels, are sensitive to the same chemotherapies as the supposed corresponding primaries (1). However, these subsets account for only 15% of all CUPs. The remaining 85% are considered to comprise an unfavorable subset, for which the reported response rate is 11.7%-65.1% and the median survival time is 6-10 months (1). Difficulty in predicting the primary site for unfavorable subsets is likely responsible for poorer therapeutic outcomes. Thus, the development of comprehensive predictive biomarkers for all relevant therapeutic agents is very important.

Recent studies have reported the successful isolation of circulating tumor cells (CTC) in metastatic malignancies (2-4). Because metastases are characteristic of CUP, patients with CUP are considered to have high CTC counts. The CellSearch system (Veridex LLC, Raritan, NL, USA) was approved for determination of CTC count by the US Food and Drug Administration. CTC analyses have been included in several clinical trials, yielding promising results (5, 6). In this study, we hypothesized that changes in CTC counts between pre-treatment and post-treatment phases with patients with CUP could be a predictive biomarker for the efficacy of ongoing treatment. To our knowledge, the literature contains no publications describing CTC count variations in CUP.

Patients and Methods

Ten patients diagnosed with CUP and treated at the Department of Clinical Oncology, Akita University Hospital from October 2012 to October 2013 were enrolled. This study was ethically-approved by the Committee of the School of Medicine of the Akita University (#1055). Written informed consent and agreement to publication were obtained from all participants of this cohort study.

Isolation of CTCs. The method used to isolate CTCs is fully-described elsewhere (8). In brief, CTCs were isolated from 20 ml of peripheral venous blood drawn from each patient, using the CellSearch kit and the CellTracks AutoPrep system (Veridex LLC). CTCs were characterized using the CellTracks Analyzer (Veridex LLC).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Clinical presentation of participants.

Results

Demographic information on the CUP cohort is presented in Table I. Patients included 6 males with an age range of 47-83 years (median=65 years). CUP histology was as follows: adenocarcinoma (n=7), spindle cell carcinoma (n=2), and NEC (n=1). Five patients were chemotherapeutically-naïve. The overall CTC detection rate was 50.0%. It was particularly high (80%, 4/5) in chemotherapeutically-naïve cases. The range of the CTCs counts per 7.5 ml of whole blood was 3-207 (median=31) at initial examination.

Among five CTC-positive patients, one did not receive chemotherapy because of his age (83 years), whereas another agreed to undergo CTC examination only once. Case 1 was a 59-year-old female (Figure 1). In September 2012, cervical LN swelling was observed and was confirmed as adenocarcinoma, but the tumor was estrogen and progesterone receptor-negative. She was referred to our Department on October 29, 2012, when 18F-fluorodeoxyglucose positron-emission tomography–computed tomography (PET-CT) revealed metastases to all lumbar vertebrae, sacrum, left subclavian LN, and right axillary LN [standardized uptake value (SUV)max 4.0-5.0)]. The CTC count was 207/7.5 ml whole blood. On November 16, 2102, carcinoembryonic antigen (CEA) was elevated to 77.1 ng/ml, carbohydrate antigen (CA)19-9 to 835.3 U/ml (normal range <37 U/ml), and CTC to 995/7.5 ml whole blood. Chemotherapy with epirubicin and cyclophosphamide (EC) was initiated. Two weeks later, CEA decreased to 2.2 ng/ml, CA19-9 to 173.2 U/ml, and CTC to 4/7.5 ml whole blood. We continued monthly EC treatment for four cycles. PET imaging on February 26, 2013 revealed a reduction in SUVmax for all positive lesions to less than 3.0, and imaging confirmed that EC treatment was effective. CTC count had predicted treatment outcome 14 days after treatment, three months earlier than imaging.

Case 2 was a 66-year-old male (Figure 2). He began to lose spatial perception in March 2013. Brain magnetic resonance imaging revealed a tumor in the right parietal lobe, and more than 20 nodular tumors (all <20 mm in diameter) were found disseminated in the cerebrum and cerebellum. CT indicated the swelling of two peripancreatic LN, a tumor in each adrenal gland, and a tumor in the left cervical region. All were considered metastatic lesions, but no primary was detected. He was referred to our Department on May 28, 2013. Abdominal LN histopathology showed small cell-like appearance. Cells were chromogranin A-, CD56- and synaptophysin-positive, and 80% of them were Ki67-positive. These findings led to the diagnosis of NEC. Whole-brain radiotherapy (30 Gy/10 fractions) was started on April 13, 2013, and chemotherapy with carboplatin and etoposide (CE) was started on May 20, 2013, when CTC counts were 31/7.5 ml whole blood. Three weeks later, CTC counts decreased to zero, but progastrin-releasing peptide (Pro-GRP) remained high at 1929 pg/ml (normal range, <81). CT performed on August 14, 2013 confirmed the status as being close to complete response (CR) by the Response Evaluation Criteria in Solid Tumors, version 1.1. for most target lesions except the left adrenal gland (74% reduction) and brain metastases, and Pro-GRP had normalized to 49 pg/ml. CE therapy was continued monthly for six cycles. Surveillance by CT and CTC conducted on October 30, 2013 confirmed the same status, and Pro-GRP was normal (57.4 pg/ml). In this case, the CTC count indicated the positive effect of CE treatment nine weeks earlier than by imaging.

Case 3 was a 64-year-old female. She had multiple bone metastases involving the ribs, the vertebrae, and the right scapula. She also had a brain tumor in the right frontal lobe and intrapelvic tumors in the right ovary and uterus. On March 25, 2013, she underwent bilateral salpingo-oophorectomy with simple hysterectomy. Histopathological examination revealed only poorly-differentiated adenocarcinoma of the right ovarian tumor. Although ovarian cancer was not completely ruled out, she was diagnosed with CUP and referred to our Department on March 19, 2013. Chemotherapy (carboplatin and docetaxel) was started on June 6, 2013. Two weeks later, CTC counts had decreased to 1/7.5 ml whole blood from 3/7.5 ml whole blood. CEA and CA125 had decreased to 1535.7 ng/ml and 191.3 U/ml (from 1887.6 ng/ml and 397.3 U/ml prior to chemotherapy), respectively, by July 3, 2103. However, the patient refused further chemotherapy because of severe watery diarrhea. Without RECIST evaluation, the reduction in CTC count corresponded to a decrease in CEA and CA125.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Clinical course of case 1. A: Changes in circulating tumor cell (CTC) count (yellow bars), and carbohydrate antigen 19-9 (CA19-9) plotted at three time points. B and C: Images showing bone metastases on the dates indicated.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Clinical course of case 2. A: Changes in circulating tumor cell (CTC) count (yellow bars) and progastrin-releasing peptide (Pro-GRP) plotted at three time points. B and C: Images showing abdominal tumors (*) on the dates indicated.

Discussion

The present study results show that CTCs can be detected in patients with CUP at a rate considerably higher than that in our previous analysis on metastatic colorectal carcinoma (38.5%) (7). CTC counts in CUP were also greater than those observed in metastatic colorectal carcinoma (median=1) (7).

In the selection of appropriate chemotherapy, two major approaches are now adopted: (i) prediction of the latent primary CUP site by expression analysis using methods such as CupPrint®; (ii) identification of target molecules in CUP (8, 9).

CTCs are considered to comprise several entities, and this heterogeneity might create a problem in the analysis of archival specimens (1). Real-time sampling, (e.g. CTC counts or circulating tumor DNA) was considered to be important (10). In the present study, changes in CTC count were apparent within a few weeks of chemotherapy initiation. Confirmation by RECIST, on the other hand, takes at least two months, and if the treatment proves ineffective, this may be unnecessarily prolonged. Although further study is required because of our limited sample size, CTC analysis seems useful in CUP.

Acknowledgements

We thank enago™ (Tokyo, Japan) for their language editing.

Footnotes

  • Conflicts of Interest

    There are no conflicts of interest to declare.

  • Received February 16, 2014.
  • Revision received May 3, 2014.
  • Accepted May 5, 2014.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Massard C,
    2. Loriot Y,
    3. Fizazi K
    : Carcinomas of an unknown primary origin diagnosis and treatment. Nat Rev Clin Oncol 8: 701-710, 2011.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Allard WJ,
    2. Matera J,
    3. Miller MC,
    4. Repollet M,
    5. Connelly MC,
    6. Rao C,
    7. Tibbe AG,
    8. Uhr JW,
    9. Terstappen LW
    : Tumour cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904, 2004.
    OpenUrlAbstract/FREE Full Text
    1. Cohen SJ,
    2. Alpaugh RK,
    3. Gross S,
    4. O'Hara SM,
    5. Smirnov DA,
    6. Terstappen LW,
    7. Allard WJ,
    8. Bilbee M,
    9. Cheng JD,
    10. Hoffman JP,
    11. Lewis NL,
    12. Pellegrino A,
    13. Rogatko A,
    14. Sigurdson E,
    15. Wang H,
    16. Watson JC,
    17. Weiner LM,
    18. Meropol NJ
    : Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6: 125-132, 2006.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Cohen SJ,
    2. Punt CJ,
    3. Iannotti N,
    4. Saidman BH,
    5. Sabbath KD,
    6. Gabrail NY,
    7. Picus J,
    8. Morse M,
    9. Mitchell E,
    10. Miller MC,
    11. Doyle GV,
    12. Tissing H,
    13. Terstappen LW,
    14. Meropol NJ
    : Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213-3221, 2008.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Hiraiwa K,
    2. Takeuchi H,
    3. Hasegawa H,
    4. Saikawa Y,
    5. Suda K,
    6. Ando T,
    7. Kumagai K,
    8. Irino T,
    9. Yoshikawa T,
    10. Matsuda S,
    11. Kitajima M,
    12. Kitagawa Y
    : Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol 15: 3092-3100, 2008.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Cohen SJ,
    2. Punt CJ,
    3. Iannotti N,
    4. Saidman BH,
    5. Sabbath KD,
    6. Gabrail NY,
    7. Picus J,
    8. Morse MA,
    9. Mitchell E,
    10. Miller MC,
    11. Doyle GV,
    12. Tissing H,
    13. Terstappen LW,
    14. Meropol NJ
    : Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223-1229, 2009.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Otsuka K,
    2. Imai H,
    3. Soeda H,
    4. Komine K,
    5. Ishioka C,
    6. Shibata H
    : Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer. Anticancer Res 33: 625-629, 2013.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Horlings HM,
    2. van Laar RK,
    3. Kerst JM,
    4. Helgason HH,
    5. Wesseling J,
    6. van der Hoeven JJ,
    7. Warmoes MO,
    8. Floore A,
    9. Witteveen A,
    10. Lahti-Domenici J,
    11. Glas AM,
    12. Van't Veer LJ,
    13. de Jong D
    . Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 26: 4435-4441, 2008.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Dova L,
    2. Pentheroudakis G,
    3. Georgiou I,
    4. Malamou-Mitsi V,
    5. Vartholomatos G,
    6. Fountzilas G,
    7. Kolaitis N,
    8. Kitsiou E,
    9. Pavlidis N
    : Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: To target or not to target? Clin Exp Metastasis 24: 79-86, 2007.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Crowley E,
    2. Di Nicolantonio F,
    3. Loupakis F,
    4. Bardelli A
    : Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10: 472-484, 2013.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 34 (6)
Anticancer Research
Vol. 34, Issue 6
June 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Utility of Measuring Circulating Tumor Cell Counts to Assess the Efficacy of Treatment for Carcinomas of Unknown Primary Origin
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Utility of Measuring Circulating Tumor Cell Counts to Assess the Efficacy of Treatment for Carcinomas of Unknown Primary Origin
KEIGO KOMINE, MASAHIRO INOUE, KAZUNORI OTSUKA, KOJI FUKUDA, HIROSHI NANJO, HIROYUKI SHIBATA
Anticancer Research Jun 2014, 34 (6) 3165-3168;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Utility of Measuring Circulating Tumor Cell Counts to Assess the Efficacy of Treatment for Carcinomas of Unknown Primary Origin
KEIGO KOMINE, MASAHIRO INOUE, KAZUNORI OTSUKA, KOJI FUKUDA, HIROSHI NANJO, HIROYUKI SHIBATA
Anticancer Research Jun 2014, 34 (6) 3165-3168;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A Tool to Estimate Survival of Elderly Patients Presenting with Metastatic Epidural Spinal Cord Compression (MESCC) from Cancer of Unknown Primary
  • Google Scholar

More in this TOC Section

  • Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis
  • Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy
  • Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib
Show more Clinical Studies

Similar Articles

Keywords

  • biomarker
  • carcinomas of unknown primary origin
  • chemotherapy
  • circulating tumor cell
  • prediction
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire